{"log_id": 4737172119067741048, "direction": 0, "words_result_num": 37, "words_result": [{"probability": {"variance": 0.008147, "average": 0.959946, "min": 0.502247}, "location": {"width": 1116, "top": 251, "height": 38, "left": 264}, "words": "疗效判定标准:完全缓解:24小时尿蛋白定量小于0.3g,且尿沉渣(RBC+5/HP,WBC"}, {"probability": {"variance": 0.002565, "average": 0.966204, "min": 0.845596}, "location": {"width": 1171, "top": 306, "height": 38, "left": 207}, "words": "5/HP、血清白蛋白、血清SCr及Ccr检测均正常。部分缓解:24小时尿蛋白定量介于0.33g"}, {"probability": {"variance": 0.010407, "average": 0.952538, "min": 0.50646}, "location": {"width": 1171, "top": 360, "height": 38, "left": 207}, "words": "之间,且下降三5U,月血清白蛋白三30g/L,且肾功能稳定。治疗头败:24小时尿蛋白定量"}, {"probability": {"variance": 0.006412, "average": 0.96226, "min": 0.591725}, "location": {"width": 1167, "top": 413, "height": 38, "left": 207}, "words": "下降<50%:或24小时尿蛋白定量介干0.3-3g之间,但血清白蛋白<30g/L;或血清SCr上"}, {"probability": {"variance": 0.018617, "average": 0.936713, "min": 0.45992}, "location": {"width": 459, "top": 472, "height": 34, "left": 203}, "words": "升及CCr下降幅变超过基础值的15"}, {"probability": {"variance": 0.001297, "average": 0.959608, "min": 0.923601}, "location": {"width": 66, "top": 529, "height": 31, "left": 260}, "words": "疗效"}, {"probability": {"variance": 0.027405, "average": 0.909537, "min": 0.389244}, "location": {"width": 1114, "top": 577, "height": 41, "left": 260}, "words": "综合疗效评价:治疗6个月后,试验组完全缓解22.22%,部分缓解59.60%;对照分别"}, {"probability": {"variance": 0.017923, "average": 0.935588, "min": 0.413375}, "location": {"width": 1171, "top": 630, "height": 41, "left": 203}, "words": "为18.84%62.32%:治疗6个月,同线水平相比,试验组和对照组均能显著降低 SLEDAI评"}, {"probability": {"variance": 0.037167, "average": 0.866079, "min": 0.370637}, "location": {"width": 1071, "top": 687, "height": 50, "left": 201}, "words": "分、降低24小时尿兰白、提高血降低S高C、.降低dsDNA阳性率"}, {"probability": {"variance": 0.021706, "average": 0.921795, "min": 0.538717}, "location": {"width": 1116, "top": 733, "height": 45, "left": 258}, "words": "试特入组病例活检的病理类型狼疣肾炎的工型、或伴有V型。其中试验组15例"}, {"probability": {"variance": 0.022048, "average": 0.929852, "min": 0.526574}, "location": {"width": 1169, "top": 792, "height": 43, "left": 201}, "words": "病例在治疗6个月后进行了重复肾活检,结果显示、米氟米特治疗后,13例患名狼疮肾炎"}, {"probability": {"variance": 0.034607, "average": 0.878515, "min": 0.376144}, "location": {"width": 1169, "top": 849, "height": 36, "left": 198}, "words": "的活动性降低,急性活动指数下降,其中,例治疗前为I、IV型,经来氟米特治疗后"}, {"probability": {"variance": 0.011941, "average": 0.950841, "min": 0.592488}, "location": {"width": 420, "top": 906, "height": 34, "left": 198}, "words": "全部转变为病理类型较轻的II型"}, {"probability": {"variance": 0, "average": 0.999724, "min": 0.999371}, "location": {"width": 118, "top": 961, "height": 34, "left": 253}, "words": "不良反应"}, {"probability": {"variance": 0.02119, "average": 0.949833, "min": 0.394961}, "location": {"width": 1107, "top": 1014, "height": 36, "left": 258}, "words": "与药物可能有关/有关的不良反应发生率,试验组为39.81%,对照组为55.26%试验组"}, {"probability": {"variance": 0.007877, "average": 0.968368, "min": 0.43311}, "location": {"width": 1174, "top": 1068, "height": 34, "left": 191}, "words": "发生率≥3%的不良事件包括:脱发、血压升高、状疱疹、转氨酶升高、腹泻/稀便、白细胞"}, {"probability": {"variance": 0.006415, "average": 0.969772, "min": 0.598804}, "location": {"width": 1167, "top": 1121, "height": 38, "left": 196}, "words": "下降、皮疹、月经不调、心悸、腹痛;发生率<的不良事件包括:恶心/呕吐、上呼吸道感"}, {"probability": {"variance": 0.006954, "average": 0.954413, "min": 0.669767}, "location": {"width": 1139, "top": 1176, "height": 36, "left": 194}, "words": "染、血小板卜降,乏力、胃烧灼感、厌食、发热、牙周疼痛、视觉异常、尿路感染、咽痛"}, {"probability": {"variance": 0.00046, "average": 0.988594, "min": 0.923732}, "location": {"width": 612, "top": 1231, "height": 36, "left": 189}, "words": "巨细胞病毒感染、体重下降、多毛、肺部感染等"}, {"probability": {"variance": 0.006962, "average": 0.967663, "min": 0.553993}, "location": {"width": 1103, "top": 1285, "height": 36, "left": 244}, "words": "期临床试验结束后,试验组52例患者自愿继续服用试验药物,服药剂量为10-30mg"}, {"probability": {"variance": 0.006579, "average": 0.963411, "min": 0.607938}, "location": {"width": 1169, "top": 1340, "height": 34, "left": 189}, "words": "日:治疗9个月后,90%的患者服药剂量减为10-20mg/日:平均随访时间32.7±18.2月,最"}, {"probability": {"variance": 0.008462, "average": 0.964536, "min": 0.562782}, "location": {"width": 1164, "top": 1393, "height": 38, "left": 185}, "words": "长观察时间为72个月:治疗6个月时,52例患者完全缓解率为35.5%,部分缓解率为44.2"}, {"probability": {"variance": 0.004864, "average": 0.974562, "min": 0.628873}, "location": {"width": 1174, "top": 1445, "height": 38, "left": 185}, "words": "经过7-72个月的继续治疗,完全缓解率为59.6%,部分缓解率为30.6%。临庆观察期间,共"}, {"probability": {"variance": 0.008456, "average": 0.962833, "min": 0.605588}, "location": {"width": 1171, "top": 1500, "height": 36, "left": 185}, "words": "有12人发生与试监药物可能有关/有关的不良反应,发生率为23.08,发生率≥的不良事"}, {"probability": {"variance": 0.01511, "average": 0.950965, "min": 0.351729}, "location": {"width": 1174, "top": 1550, "height": 41, "left": 182}, "words": "包括:白细胞下降、转氨酶升高、血小板减少;发生率<3%的不良事件包括:上呼吸道感"}, {"probability": {"variance": 0.004327, "average": 0.96712, "min": 0.768476}, "location": {"width": 557, "top": 1610, "height": 36, "left": 180}, "words": "染、脱发、带状疱疹、月经不调、尿路感染"}, {"probability": {"variance": 0.001469, "average": 0.975403, "min": 0.895194}, "location": {"width": 153, "top": 1665, "height": 34, "left": 194}, "words": "【药理毒理】"}, {"probability": {"variance": 0.011459, "average": 0.952293, "min": 0.520822}, "location": {"width": 1174, "top": 1715, "height": 41, "left": 178}, "words": "木品为一个具有抗增殖活性的异哂唑类免疫抑制剂,其作用机理主要是抑制二氢乳清酸脱氢"}, {"probability": {"variance": 0.009468, "average": 0.963956, "min": 0.48523}, "location": {"width": 1176, "top": 1770, "height": 38, "left": 175}, "words": "酶的活性。从而影响活化淋巴细胞的嘧啶合成。体内外试验表明本品具有抗炎作用。来氟米"}, {"probability": {"variance": 0.00608, "average": 0.959876, "min": 0.712822}, "location": {"width": 751, "top": 1827, "height": 34, "left": 173}, "words": "特的体内活性主要通过其活性代谢产物A771726(M1)画产生"}, {"probability": {"variance": 0.00034, "average": 0.991146, "min": 0.949958}, "location": {"width": 189, "top": 1879, "height": 36, "left": 182}, "words": "【药代动力学"}, {"probability": {"variance": 0.001847, "average": 0.975177, "min": 0.85201}, "location": {"width": 1176, "top": 1932, "height": 38, "left": 173}, "words": "本品口服吸收迅速,在胃肠粘膜与肝中迅速转变为活性代谢产物A771726(M1),口服后6-12"}, {"probability": {"variance": 0.006523, "average": 0.97043, "min": 0.504263}, "location": {"width": 1146, "top": 1984, "height": 38, "left": 173}, "words": "小时内A771726的血药浓度达峰值,口服生物利用度(F)约80%,吸收不受高脂肪饮食影响"}, {"probability": {"variance": 0.011279, "average": 0.95889, "min": 0.446026}, "location": {"width": 1178, "top": 2041, "height": 36, "left": 169}, "words": "单次口服50mg或100ng后24小时,血浆A771726浓度分别为4g/ml或8.5jg/mlA771726"}, {"probability": {"variance": 0.017374, "average": 0.938345, "min": 0.488527}, "location": {"width": 1176, "top": 2094, "height": 38, "left": 169}, "words": "上要分布于肝、肾和皮肤组织,而脑组织分布较少:A771726血浆浓度较低,血浆蛋白结合率"}, {"probability": {"variance": 0.011525, "average": 0.956608, "min": 0.401802}, "location": {"width": 1178, "top": 2147, "height": 43, "left": 164}, "words": "大于99%,稳态分布容积为0.13L/KgA771726在体内进一步代谢,并从肾与胆汁排泄,其"}, {"probability": {"variance": 0.016862, "average": 0.91908, "min": 0.661923}, "location": {"width": 123, "top": 2215, "height": 29, "left": 692}, "words": "第4/5页"}], "language": 3}